A Phase 2 interventional study of 400 ug Brimonidine Implant and 200 ug Brimonidine Implant in Rhegmatogenous Macula-off Retinal Detachment, sponsored by Allergan. Completed at 6 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-24.
Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Retinal Detachment with a site in United States — 3 open to participants now, 3 under way, 1 of them phase 3. Retinal Detachment · United States.
Among the 32 studies in Retinal Detachment with a site in United States, this one is the 12th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 5 in phase 2, and was the 5th registered.
199 studies on the registry are indexed under Retinal Detachment; 29 are open to participants now.
Browse Retinal Detachment studies →3 of the 32 studies in Retinal Detachment with a site in United States are open now. Recruiting first, the newest first:
Helen Keller Eye Research Foundation · Sites in United States
Duke University · Sites in United States
Ages 4 wk+ · Healthy volunteers
Wills Eye · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 21 Retinal Detachment studies recruiting now, 15 (71%) set no upper age limit and 4 (19%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 4 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 44 is below the median of 50 across 132 interventional studies indexed under Retinal Detachment.
Median enrollment 40 across the 27 interventional studies, 750 across the 5 observational. Of the 27 that completed or were terminated, 11 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 1 study filed under Retinal Detachment — fewer than ten, so there is no comparison to draw.
1 of the studies in Retinal Detachment with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03713268Duke UniversityIntraoperative OCT Guidance of Intraocular Surgery II | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Retinal Detachment with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of the Brimo PS DDS® Applicator System (200 μg and 400 μg brimonidine tartrate) on visual function in patients with previous rhegmatogenous macula-off retinal detachment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
Drug: 400 ug Brimonidine Implant
200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
Drug: 200 ug Brimonidine Implant
Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
Other: Sham (no implant)
400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
Also known as: Brimonidine Tartrate PS DDS®
200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
Also known as: Brimonidine Tartrate PS DDS®
Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. The percentage of patients with at least a 15-letter increase in BCVA in the study eye is reported.
Time frame: Month 3
Change From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
Time frame: Baseline, Month 3
Percentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit
IOP is the fluid pressure inside the eye. The percentage of patients with IOP \< 10 millimeters of mercury (mmHg) in the study eye at any follow up visit is presented.
Time frame: 12 Months
| Milestone | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Started | 15 | 15 | 14 |
| Completed | 13 | 15 | 13 |
| Not completed | 2 | 0 | 1 |
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters). The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly indicates that vision has improved. The percentage of patients with at least a 15-letter increase in BCVA in the study eye is reported.
| Percentage of Patients | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Percentage of Patients With at Least a 15-Letter Increase From Baseline in Best Corrected Visual Acuity (BCVA) in the Study Eye | 6.7 | 6.7 | 0 |
BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). A positive change from baseline indicates an improvement and a negative change from baseline indicates a worsening.
| Number of Letters Read Correctly | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Baseline | 46.6 ± 13.69 | 53.3 ± 8.46 | 50.3 ± 10.92 |
| Change from Baseline at Month 3 | 6.0 ± 6.23 | 3.1 ± 6.78 | 4.8 ± 4.64 |
IOP is the fluid pressure inside the eye. The percentage of patients with IOP \< 10 millimeters of mercury (mmHg) in the study eye at any follow up visit is presented.
| Percentage of Patients | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Percentage of Patients With Intraocular Pressure (IOP) < 10 mmHg in the Study Eye at Any Follow up Visit | 20.0 | 26.7 | 28.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 ug Brimonidine Implant | — | 0/15 (0%) | 7/15 (46.7%) |
| 200 ug Brimonidine Implant | — | 2/15 (13.3%) | 12/15 (80%) |
| Sham (no Implant) | — | 2/14 (14.3%) | 9/14 (64.3%) |
| Event | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Prostate Cancer [y]Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 1/10 | 0/9 |
| Myocardial InfarctionCardiac disorders | 0/15 | 0/15 | 1/14 |
| Strabismus CorrectionSurgical and medical procedures | 0/15 | 0/15 | 1/14 |
| HaemorrhoidsGastrointestinal disorders | 0/15 | 1/15 | 0/14 |
| Event | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) |
|---|---|---|---|
| Conjunctival HaemorrhageEye disorders | 3/15 | 1/15 | 2/14 |
| Eye PainEye disorders | 1/15 | 3/15 | 1/14 |
| Conjunctival HyperaemiaEye disorders | 2/15 | 1/15 | 1/14 |
| Eye PruritusEye disorders | 2/15 | 0/15 | 0/14 |
| Hypotony of EyeEye disorders | 1/15 | 2/15 | 0/14 |
| Intraocular Pressure DecreasedInvestigations | 1/15 | 2/15 | 0/14 |
| DepressionPsychiatric disorders | 0/15 | 2/15 | 0/14 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 1/10 | 0/9 |
| Conjunctival OedemaEye disorders | 1/15 | 1/15 | 1/14 |
| Retinal HaemorrhageEye disorders | 1/15 | 0/15 | 1/14 |
| Age Continuous(Years) | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) | Total |
|---|---|---|---|---|
| Mean | 54.2 ± 17.12 | 54.3 ± 20.36 | 56.1 ± 15.19 | 54.9 ± 17.35 |
| Sex: Female, Male(Participants) | 400 ug Brimonidine Implant | 200 ug Brimonidine Implant | Sham (no Implant) | Total |
|---|---|---|---|---|
| Female | 6 | 5 | 5 | 16 |
| Male | 9 | 10 | 9 | 28 |
The record gives a start of Nov 2009, a primary completion of Oct 2010 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 2 years 6 months after primary completion. A results delay was requested in Oct 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine